RELPI
The Real Estate Limited Partner Institute (RELPI) today announced the expansion of its compelling Interests Aligned programs to Europe and the United Kingdom with the appointment of institutional real estate investment and media professional Arno Van Grondelle as CEO of RELPI Europe.
RELPI’s intimate, focused and curated local meet-ups foster open conversation and deep relationships among leading stakeholders in the investment and allocation of capital in real estate. The series was formally launched in 2021 with events in Austin, New York and Philadelphia, and was met with an overwhelming interest and attendance. In addition to the expansion into Europe and the United Kingdom, RELPI has announced events in Chicago, Cleveland, Los Angeles, San Francisco and New York so far in 2022.
“Our success and expansion reflect the pent-up demand for in-person gatherings and virtual meetings of informed, high-level executives to share insights, ideas and transparent conversations devoted to best practices in institutional real estate asset allocation and investment,” said RELPI’s CEO and Executive Director Jonathan Schein. “In less than six months, the RELPI community has grown to include more than 125 pension funds, endowments foundations and family offices, as well as more than 50 fund managers.”
The addition of Arno Van Grondelle as CEO of RELPI Europe will accelerate this expansion. Mr. Van Grondelle brings extensive knowledge and leadership experience from his many years working in the institutional real estate investment and media industries. Most recently he served as Managing Director of Europe at Institutional Real Estate Inc., responsible for client relations, business development and sales for Institutional Real Estate Europe magazine. He previously served as International Sales Director at PropertyEU, where he was responsible for the sales of PropertyEU's comprehensive media portfolio, including PropertyEU magazine and EXPO Real's Preview and Daily News.
"Arno’s wealth of knowledge, experience and relationships in the European investor and LP arena will solidify RELPI’s fast mover status in the industry,” said Mr. Schein "His professionalism and market acumen will make a great addition to our growing platform designed to connect key players for the mutual benefit of the dynamic private equity real estate investment and capital industries.”
“I am very excited to join RELPI and further build this community in Europe,” said Mr. Van Grondelle. “We are dedicated to bringing together real estate institutional investors, fund managers, operating companies and those organizations allied to the industry on a local, regional and global scale.”
The Interests Aligned series are designed to be streamlined and efficient (just three hours long) with a strong emphasis on social networking, offering RELPI’s unique value proposition – intimate, ultrahigh-value gatherings, in a streamlined, economically effective manner, with “proximity” in mind.
For more information about the Interests Aligned series, to register or inquire about membership, please visit: www.RELPI.org
About RELPI
As an established producer of successful meetings, events and conferences devoted to the global institutional investment community for the commercial real estate class, with “proximity” as the prime value proposition, RELPI is perfectly positioned to deliver a best-of-both-worlds solution: intimate, ultrahigh-value gatherings in a streamlined, economically effective way. From “virtual salons” and global summits focused on investors in all major global markets, to emerging manager programs and even “private label,” bespoke roundtables, RELPI is enabling tomorrow’s business connectivity today.
https://www.relpi.org
View source version on businesswire.com: https://www.businesswire.com/news/home/20220104005129/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom